Sphere Fluidics introduces Cyto-Cellect Human IgGK Detection Kit

Sphere logo

 

Sphere Fluidics introduces Cyto-Cellect Human IgGK Detection Kit

  • First in a new range to advance identification and selection of cells with the highest productivity

  • Assay-ready reagent kit to reduce timelines and enhance efficiency in cell line development

Cambridge, UK, 9 September 2019: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, today introduced the Cyto-Cellect™ Human IgGK Detection Kit, to be used in conjunction with the Cyto-Mine® Single Cell Analysis System for rapid and cost-effective measurement of antibody class and productivity in cell line development.

The Cyto-Cellect Human IgGK Detection Kit has been developed to provide Cyto-Mine users with an easy-to-use, standardized assay format for the detection of secreted human antibodies in picodroplets. The sensitive FRET-based assay rapidly detects the presence of human IgG with kappa light chain after secretion from encapsulated cells, to characterize and measure antibody production. Rapid detection of IgG enables high-throughput identification and selection of cells with the highest productivity for more efficient cell line development.

With optimized ratios of Sphere Fluidics’ Human IgGK Detection probes, the Cyto-Cellect Human IgGK Detection Kit offers a sensitive and robust assay ideal for streamlining cell isolation and titer determination. The complete kit has been manufactured without the use of animal-derived materials, offering an animal-origin-free reagent kit that provides confidence in the reproducibility and consistency of the assay and conforms to regulatory requirements in cell line development.

Dr Zoe Nilsson, Global Product Marketing Manager, Sphere Fluidics, said: “Our expert team has applied extensive knowledge of assay requirements to develop the Cyto-Cellect Human IgGK Detection Kit, offering users a sensitive, yet robust assay solution for the Cyto-Mine platform. The addition of this assay-ready kit to Sphere Fluidics’ product portfolio provides a rapid, yet cost-effective solution to further support and reduce cell line development timelines.”

The Cyto-Mine platform will be on display in Boston, MA at BioProcess International from 9–12 September 2019 (Stand #1306).

For more information about Sphere Fluidics’ Cyto-Cellect Human IgGK Detection Kit, please visit spherefluidics.com/cyto-cellect-human-iggκ-detection-kit 

 

We are excited to release our latest software update with new Cyto-Mine® functionalities!

Sphere logo

 

We are excited to release our latest software update with new Cyto-Mine® functionalities!

 

The Cyto-Mine® Studio Suite contains a collection of software to allow Cyto-Mine® operation and data acquisition. The release of this updated version of the Cyto-Mine® Studio Suite brings with it a collection of improvements and new functionalities to further enhance your Cyto-Mine® workflow.

We have highlighted some of the new functionalities and their benefits below.

Pooled Picodroplet Dispensing

What is it?

Pooled Picodroplet Dispensing allows user to dispense all of the sorted picodroplets (containing selected cells of interest) into one well of a microtiter plate.

What’s the benefit?

Pooled Picodroplet Dispensing enables the dispensing of the whole sorted population (containing selected cells of interest) which is beneficial when you need a little more sample for further downstream analysis, or you would like to collect the vast majority the ‘hits’.

What’s the application?

Screening of an entire B cell population in Antibody Discovery.

The picodroplet technology of Cyto-Mine® enables the screening of millions of B cells by the encapsulation of multiple cells per picodroplet. The cells are then assayed to find antibody-secreting cells using an IgG detection assay. Pooled Picodroplet Dispensing provides the function to be able to dispense all picodroplets containing antibody-secreting cells into one well of a microtiter plate. The cells can then be released from the picodroplets and cultured overnight ready for a second round of screening on day 2 using an antigen-specific assay to detect the rare B cells of interest.

Pooled Picodroplet Dispensing allows the processing of tens of millions of cells to a small population of one or more single hit cells within 2 days.

Download Pooled Picodroplet Dispensing Protocol

 

Barcode Scanning

What is it?

Another great feature for our users, the incorporation of barcode scanning provides tracking of picodroplets and Cyto-Mine® experiments. All data from detected, sorted and dispensed picodroplets is saved in the local Cyto-Mine® database along with experiment configuration parameters and assay results, allowing centralized archiving of experimental data and improved performance of the enhanced data analysis software.

What’s the benefit?

The addition of the barcode scanner improves traceability of experiments as dispensed picodroplets are associated with their destination plate when the barcode is scanned.

Automation from Priming to Flow

What is it?

All Cyto-Mine® assays are now automatically progressed from the Cyto-Cartridge® Priming step to the end of Incubation.  Consequently, no user interaction is required during the entire Cyto-Cartridge® Priming, Picodroplet Generation and Incubation workflow.

What’s the benefit?

The automation of these stages removes the requirement for any user interaction resulting in a more streamlined, hands-off workflow.

Variable Picodroplet Generation

What is it?

During Pre-Experiment Configuration the quantity of picodroplets generated in an experiment can be selected from three options of 1 million, 1.5 million or 2 million picodroplets. 1.5 million picodroplets remains the default picodroplet generation value.

What’s the benefit?

The ability to alter the number of picodroplets generated offers users with rare precious samples the option to generate a smaller number of picodroplets or, if you have excess sample, the opportunity to increase the number of picodroplets generated to minimise the amount of unused cell sample.

 

For further information please contact:

Sphere Fluidics
Dr Zoe Nilsson
Global Product Marketing Manager
Tel: +44 (0)1223 628892
Email: Zoe.Nilsson@spherefluidics.com

 

About Sphere Fluidics www.spherefluidics.com
Sphere Fluidics develops and manufactures single cell analysis and monoclonality assurance systems for biologics discovery and cell line development.

Sphere Fluidics’ Cyto-Mine® System integrates selective screening of tens of millions of single cells, sorting, dispensing, imaging and clone verification into a single automated platform to streamline workflows, reduce costs, improve throughput and enable high-value clones to be captured in a single run. Cyto-Mine® is underpinned by the Company’s patented, microfluidic picodroplet technology.

Sphere Fluidics is located in Babraham, Cambridgeshire (UK) and Monmouth Junction, New Jersey (USA). The Company has also internationalized its business via a global network of distributors.

Sphere Fluidics expands into additional facility at Granta Park in Cambridge, UK

Sphere logo

 

Sphere Fluidics expands into additional facility at Granta Park in Cambridge, UK

 

  • New offices at leading science hub support the Company’s rapid growth following recent investment

  • New facility is in addition to headquarters at Babraham Research Campus, Cambridgeshire, UK and offices in Monmouth Junction, New Jersey, USA

 

Cambridge, UK, 21 August 2019: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has opened a new office space at Granta Park in Cambridgeshire, UK. The new facilities support the Company’s accelerated expansion and accommodate its plans for further growth.

Sphere Fluidics recently closed a $4.8 million USD (£3.7 million) funding round, enabling it to hire 10 new staff to expand commercial capabilities and facilitate service and support for its Cyto-Mine® Single Cell Analysis System. Sphere Fluidics sales, marketing, finance and operations teams join the specialist skills pool at Granta Park, one of the UK’s leading life-science research parks, positioned within the Cambridge Science Cluster, taking 1,038sq. ft in the McClintock Building. The Park is home to over 2,500 people and multiple organizations, placing the Company in close proximity to high-quality research and commercialization activity, and opening up the opportunity for further collaborations with potential partners, researchers and suppliers based on the campus.

Sphere Fluidics’ new facilities at Granta Park are in addition to its offices at Babraham Research Campus, Cambridgeshire, UK and Monmouth Junction, New Jersey, USA. The Company also has an established network of international distributors in Japan, France, China, Switzerland, Germany, Austria, Benelux, Australia, Scandinavia and Korea.

Rob Treanor, Director of Operations, Sphere Fluidics, commented: “Recent investment has enabled Sphere Fluidics to accelerate its plans to expand commercial and scientific activities and we are now raising further funding to invest in more new hires and increase our presence in not only the UK but also, the US. It is vital that we are positioned in locations with a flexible and innovative network and look forward to joining the collaborative culture at Granta Park to support these growth projections.”

 

Sphere Fluidics at Granta Park Cambridge

McClintock Building, Granta Park

Rob Treanor, Director of Operations, Sphere Fluidics

For further information please contact:

Sphere Fluidics
Dr Frank Craig, CEO
Tel: +44 (0)1223 628890
Email: frank.craig@spherefluidics.com

Zyme Communications
Dr Michelle Ricketts
Tel: +44 (0)7789 053885
Email: michelle.ricketts@zymecommunications.com

About Sphere Fluidics www.spherefluidics.com
Sphere Fluidics develops and manufactures single cell analysis and monoclonality assurance systems for biologics discovery and cell line development.

Sphere Fluidics’ Cyto-Mine® System integrates selective screening of tens of millions of single cells, sorting, dispensing, imaging and clone verification into a single automated platform to streamline workflows, reduce costs, improve throughput and enable high-value clones to be captured in a single run. Cyto-Mine® is underpinned by the Company’s patented, microfluidic picodroplet technology.

Sphere Fluidics is located in Babraham, Cambridgeshire (UK) and Monmouth Junction, New Jersey (USA). The Company has also internationalized its business via a global network of distributors.

Follow Sphere Fluidics on Twitter @SphereFluidics and LinkedIn @Sphere Fluidics Limited.

About Granta Park www.grantapark.co.uk
Granta Park is Cambridge’s leading life-science research park and extends to 120 acres in total. It is a low-density research park, located at the heart of Europe’s strongest and most dynamic cluster of life science and technology-based companies.

Many of these companies were founded to commercialise research that was spun out of the UK’s top-ranked University of Cambridge which is located six miles away. The Park, with planning consent, has been developed exclusively for high-tech companies involved in research and development. Work on the green-field site for Granta Park commenced in 1998 and since that time has grown to 1 million square feet of laboratory and office space with 2,500 people working on the park each day.

 

 

 

 

 

Sphere Fluidics closes a $4.8 million USD (£3.7 million) Funding Round

Sphere logo

 

Sphere Fluidics closes a $4.8 million USD (£3.7 million) Funding Round

 

  • New funding of $2.9 million USD (£2.2 million) is in addition to the $2 million (£1.5 million GBP) investment (announced in January 2019), brings the total raised to $4.8 million USD (£3.7 million GBP)

  • Lead investors were Greenwood Way Capital and 24Haymarket Limited

  • Funding will be used to further expand operations in the UK and USA

 

Cambridge, UK, 10 June 2019: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has closed an additional tranche of investment of $2.9 million (£2.2 million), securing a total of $4.8 million (£3.7 million) in investment. The funding will be used as working capital for the Company’s Cyto-Mine® Single Cell Analysis System, expansion of the UK facility and enable the doubling of personnel through the opening of a new US Sales Office and Demo Lab in California.

The funding round was led by Greenwood Way Capital whose members, which included several international family offices, invested a total of $4.3 million (£3.3 million), alongside 24Haymarket Limited and other individual investors.

Sphere Fluidics’ Cyto-Mine® is an automated platform which integrates single cell screening, sorting, dispensing, imaging and clone verification. It can process up to 40 million cells per day and assesses and isolates those that produce a specific antibody or biologic to help streamline workflows and improve throughput in biologics discovery and cell line development.

Frank F Craig PhD MBA, CEO, Sphere Fluidics, commented: “We are delighted to raise this additional funding. Due to our over-subscribed investment round earlier this year, we decided to add on a second tranche to accommodate the additional interest. We are currently recruiting and looking at prospective new facilities in the UK and California to support the growth of our commercial and scientific activities.” 

Ian Leigh, Founder, Greenwood Way Capital commented: “We are very pleased to have been able to assist Sphere Fluidics once again and to have introduced them to suitable investors for their various funding stages. This was our fourth funding round with them. Our members range from high net worth individuals to large family offices which have enabled us to support the Company from its early stage investment rounds to the recent larger scale-up fundraising. It has been exciting to have worked with such a professional team developing such a unique technology.

Ian Leigh and Frank Craig
Ian Leigh (left), Founder, Greenwood Way Capital and Dr Frank Craig (right), CEO, Sphere Fluidics

 

For further information please contact:

 

Sphere Fluidics
Dr Zoe Nilsson
Tel: +44 (0)1223 804200
Email: Zoe.Nilsson@spherefluidics.com

Greenwood Way Capital
Mr Ian Leigh BSc MBA
E-mail: Ian@gwc.london

24Haymarket Limited
Mr Paul Tselentis BA
E-mail: Paul@24Haymarket.com

Zyme Communications
Dr Michelle Ricketts
Tel: +44 (0)7789 053885
Email: michelle.ricketts@zymecommunications.com

About Sphere Fluidics www.spherefluidics.com

Sphere Fluidics develops and manufactures single cell analysis and monoclonality assurance systems for biologics discovery and cell line development. Sphere Fluidics’ Cyto-Mine® System integrates selective screening of tens of millions of single cells, sorting, dispensing, imaging and clone verification into a single automated platform to streamline workflows, reduce costs, improve throughput and enable high-value clones to be captured in a single run. Cyto-Mine® is underpinned by the Company’s patented, microfluidic picodroplet technology. Sphere Fluidics is located in Babraham, Cambridgeshire (UK) and Monmouth Junction, New Jersey (USA). The Company has also internationalized its business via a global network of distributors.

About Greenwood Way Capital www.gwc.london

Greenwood Way Capital is a network of investors, which include, funds, family offices and individuals, which invest in early stage companies. The investment opportunities are usually early-stage UK companies which have innovative ideas or unique disruptive technologies and are led by highly entrepreneurial management. Our deal size ranges from £500,000 to £5 million.

About 24Haymarket Limited www.24haymarket.com

24Haymarket Limited is a premium deal-by-deal investment platform focused on high-growth businesses, investing up to £5 million in any particular company. 24Haymarket’s Investor Network includes several highly experienced private equity and venture capital investors, seasoned entrepreneurs and senior operators. We invest our own capital in direct alignment with entrepreneurs and typically seek Board representation to actively support their growth agenda. Since its inception in 2011, 24Haymarket has invested in more than 50 high-growth businesses.

Sphere Fluidics hires 10 new UK and US staff in its plan to scale internationally

Rob Treanor joins as Director of Operations and Andrew Campbell as Director of Finance

 

Cambridge, UK, 26 March 2019: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has appointed six new employees and plans to hire four more staff in its UK and US sites. Rob Treanor and Andrew Campbell join Sphere Fluidics as Director of Operations and Director of Finance, respectively alongside new hires to its sales, operations and scientific teams. These appointments will expand the Company’s commercial capabilities and facilitate service and support for new and existing Cyto-Mine® customers in both the UK and US.

Rob Treanor joins Sphere Fluidics as Director of Operations and will be responsible for the manufacturing, supply chain and quality control. He will drive commercial operations and streamline processes to extend Sphere Fluidics’ product offering and deliver services to more customers. He has extensive experience running large logistics and supply teams within the biotechnology sector.

Sphere Fluidics has also appointed Andrew Campbell as its Director of Finance. Andrew has 20 plus years of financial management experience in financial planning, statutory reporting, cash management, tax and UK and US GAAP. He previously held senior positions at various global Life Sciences companies including, Charles Rivers and Perkin Elmer Life Sciences.

The Company has also made key appointments to its US Field Applications and Service Engineering teams to expand services and support for new and existing customers across North America. They will be supporting researchers in utilizing the Cyto-Mine® Single Cell Analysis System to help customers identify and isolate rare cells of interest for biotherapeutic discovery and cell line development. Additionally, hires in marketing, product management and sales have been made.

Dr Rob Marchmont, VP of Sales and Marketing, Sphere Fluidics, said: “These hires follow Sphere Fluidics’ recent successful fundraising round and strong early market acceptance of our flagship Cyto-Mine® instrument requiring us to expand and strengthen our commercial operations.”

Rob Treanor, Director of Operations, Sphere Fluidics, commented:I am passionate about quality, efficiency and continuous improvement, and I’m excited to implement these qualities across operations at Sphere Fluidics, particularly at this pivotal and exciting stage of the Company’s growth.

Andrew Campbell, Director of Finance, Sphere Fluidics, commented:I look forward to growing Sphere Fluidics’ Finance team as we strive to deliver outstanding financial performance and growth at this critical moment of international expansion.”

For more information about Sphere Fluidics’ team, please visit:

https://spherefluidics.com/about-us/management-team

Oxford Genetics and Sphere Fluidics announce a multi-partner collaboration to expedite the development of automated microfluidic systems for rapid and high-throughput gene editing in mammalian cell lines

 

18 February 2019 – Oxford: Oxford Genetics and Sphere Fluidics announce a multi-partner collaboration to expedite the development of automated microfluidic systems for rapid and high-throughput gene editing in mammalian cell lines.

Under the agreement, Sphere Fluidics will act as the lead partner, looking to utilise its extensive expertise in microfluidic systems to produce new products designed to meet the requirements of multiplexed gene editing workflows.

Oxford Genetics and the University of Edinburgh will provide input into industrial and application specific requirements, both in relation to standard engineering approaches but also for more difficult host systems, including stems cells and primary cell lines, and in discovery contexts. Twist Bioscience will contribute DNA synthesis capabilities and required reagents for the project.

“Gene editing, particularly CRISPR technologies, have revolutionised the way scientists are able to engineer mammalian cells for a wide-variety of applications. While these technologies are highly efficient, there is a requirement to further optimise the way laboratories deliver the CRISPR tools to cells and interrogate the resultant products. By increasing throughput and reducing timelines in this area, this creates new avenues of research and commercial applications, from our ability to address complex genetics in basic biology to utilising big data to facilitate personalised medicine,” said Tom Payne, CSO at Oxford Genetics. This forms part of Oxford Genetics on-going commitment to automating laboratory processes and facilitating intelligent experimental design and data handling.

“We are very pleased to join forces with a company of the calibre of Oxford Genetics. They bring excellent expertise in cell biology, gene editing and workflow automation. We plan to develop a desktop system that will miniaturise and automate the genome editing of single cells. Such a product is highly innovative and will be disruptive in that sector. This system will enable scientists to easily perform automated genome editing and create new cell lines and valuable biomedical products,” said Frank F. Craig, CEO at Sphere Fluidics.

“This multi-partner collaboration brings together the incredible expertise of different organisations to fuel important and cutting-edge responsible research in the field of gene editing,” commented Emily M. Leproust, Ph.D., CEO of Twist Bioscience. “CRISPR holds tremendous promise to truly improve health and eliminate disease, and we are thrilled to support the scaling of these combined technologies to work toward improved health worldwide.”

Sphere Fluidics closes $2 million USD (c. £1.5 million GBP) investment round

  • Investment received from Greenwood Way Capital, Oxford Technology and Innovations EIS Fund and 24Haymarket
  • Funding will be used to accelerate growth in operations and sales across the UK and USA

Cambridge, UK, 29 January 2019: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, announced today that is has closed a $2 million (circa £1.5 million) investment round. The Company secured funding from several investors including Greenwood Way Capital, Oxford Technology and Innovations EIS Fund and 24Haymarket. The funds raised will be used to accelerate growth in operations and support sales of its Cyto-Mine® Single Cell Analysis System.
Sphere Fluidics’ Cyto-Mine is an automated platform which integrates single cell screening, sorting, dispensing, imaging and clone verification. It can process up to 40 million cells per day, and assesses and isolates those that produce a specific biologic to help streamline workflows and improve throughput in antibody discovery and cell line development. The Company will use the investment to expand operations and sales capabilities across the UK and USA and open a new US West Coast Sales Office.
 Frank F Craig PhD MBA, CEO, Sphere Fluidics, said: “We are pleased to see such a high level of interest in Sphere Fluidics and receive funding from several leading investors. We are making further investment in automating and streamlining our manufacturing processes across our product range to extend our offering and to deliver our high-quality standards and service to more researchers working in biotherapeutic discovery and cell line development across the UK and USA. We will be raising additional funds to expand these capabilities further.”
Cyto-Mine will be on display in Washington, DC at SLAS 2019 from 2nd to 6th February 2019 (Booth #1655 and #1429).
For more information about Sphere Fluidics and Cyto-Mine, please visit:
https://spherefluidics.com/products/integrated-systems/cyto-mine/

Sphere Fluidics is a finalist in the Medicine Maker Innovation Awards and now needs a public vote.

We have been voted as one of the most groundbreaking technologies of 2018 in the Medicine Maker Innovation Awards!
The Medicine Maker Innovation Awards highlight the most groundbreaking drug development and manufacturing technologies released onto the market over the course of the year and we are honoured to have Cyto-Mine® nominated as one of the top 16 technologies showcased.
The Medicine Maker is now looking for votes for which innovation out of the top 16 is truly the most innovative!
We need support from our users and vendors to become the favourite in their online vote. Voting will close on February 28, 2019.
Vote for Cyto-Mine® here: 

Sphere Fluidics collaborates with Peak Analysis and Automation to increase throughput in antibody discovery and cell line development

PAA’s S-LAB micro-plate handling capability will be integrated with Sphere Fluidics’ Cyto-Mine Single Cell Analysis System

Cambridge and Farnborough, UK, 15 January 2019: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, and Peak Analysis and Automation (PAA), a leader in the industry for the design and manufacture of automated laboratory equipment, will collaborate to offer automated micro-plate handling capabilities for single cell analysis. PAA’s S-LAB™ plate handler will be integrated with Sphere Fluidics’ Cyto-Mine® Single Cell Analysis System to help increase throughput in antibody discovery and cell line development.

Sphere Fluidics’ Cyto-Mine is an automated platform which combines single cell screening, sorting, isolation and clone verification, alleviating the need for separate instruments. Its application programming interface (API), introduced as part of the updated Cyto-Mine Studio Software Suite in 2018, enables easy communication with PAA’s innovative S-LAB automated plate handler. The integration of micro-plate handling with the Cyto-Mine will help to reduce hands-on intervention to further streamline biopharmaceutical workflows.

Dr Frank Craig, CEO, Sphere Fluidics, commented: “Our Cyto-Mine is compatible with 96- and 384-well microtiter plates, providing a high-throughput platform for single cell analysis. By combining this with the easy-to-use automated plate handler from Peak Analysis and Automation we will be able to offer improved throughput capabilities to help reduce timelines in biotherapeutic discovery and cell-line development.”
Dr Malcolm Crook, Technical Director, Peak Analysis and Automation, said: “Our small, affordable plate handler with the reliability of a robotic arm will offer users of Sphere Fluidics’ award-winning Cyto-Mine system a simple and flexible solution to further improve workflows and reduce costs associated with a more labor-intensive approach.”
 

Cyto-Mine will be on display in Washington, DC at SLAS 2019 from 2nd to 6th February 2019 (Booth #1655 and #1429).
For further information about Sphere Fluidics and Cyto-Mine, please visit: https://spherefluidics.com/products/integrated-systems/cyto-mine/
For further information about PAA’s lab automation systems, please visit: https://www.paa-automation.com/products/automated-platehandlers/
 

Cyto-Mine® Single Cell Analysis System (right) and S-LAB™ automated plate handler (left)